Cipla files defensive patent suit over Ofev generic
Mumbai-based pharma company Cipla has filed a lawsuit asking a Delaware court to rule that its proposed generic of Boehringer Ingelheim’s lung disease treatment Ofev does not infringe two patents.
Moderna pledges to not enforce COVID-19 patents in 92 states
Moderna has stated that it will “never” enforce its COVID-19 patents in 92 low and middle-income countries.
Regeneron can’t dodge Allele’s COVID patent suit
Regeneron has failed to convince a Manhattan district court to drop a lawsuit claiming that it developed COVID-19 treatments using Allele’s fluorescent protein invention without its permission.
US Chamber of Commerce warns against COVID-19 waiver
The US Chamber of Commerce has warned against the proposed Covid-19 IP waiver, in its latest International IP Index, a report measuring the quality of global IP systems.
Harvard, 10x accuse NanoString of infringing gene sequencing tech
Harvard College and 10x Genomics have sued Nanostring Technologies, alleging that the company’s CosMx imaging platform infringes two patents covering “gene-mapping” technology.
USPTO rules Broad owns CRISPR animal cell editing patents
Patents core to the breakthrough gene-editing technology CRISPR belong to the University of Harvard and the Massachusetts Institute of Technology’s Broad Institute, the US Patent and Trademark Office has ruled.
Ono sues AstraZeneca over antibody patents
Japan-based Ono Pharmaceuticals has sued AstraZeneca, accusing the US pharma company of infringing patents covering an antibody used in cancer treatment.
Arbutus, Genevant sue Moderna over COVID-19 vaccine tech
Arbutus Biopharma and Genevant Sciences are jointly suing Moderna over royalties from the sales of its COVID-19 vaccine, which allegedly uses their tech for a drug-delivery system without authorisation.
A&O recruits five-strong Goodwin team, launches in Boston
Allen & Overy has hired five partners from Goodwin Procter to boost its US life sciences litigation practice.
AstraZeneca sues Taro in blood-thinning drug patent dispute
AstraZeneca has sued Taro Pharmaceuticals in two US federal courts alleging that Taro’s planned generic blood-thinning treatment infringes a patent for its Brilinta (ticagrelor) medication.
